Nitrated-fatty acids modulation of type II diabetes
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsBruce A. Freeman, Francisco J. Schopfer
Life of this patent
Estimating the term…
Abstract
Nitro oleic acid and related metabolites are agonists of PPAR-γ. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-γ, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-γ.
Claims4
An oral unit dosage form comprising a pharmaceutical composition, the pharmaceutical composition comprising (A) 10-nitro-octadecenoic acid, or a pharmaceutically acceptable salt or prodrug thereof, and (B) a pharmaceutically acceptable carrier.
An oral unit dosage form comprising a pharmaceutical composition comprising (A) 9-nitro-octadecenoic acid, or a pharmaceutically acceptably salt or prodrug thereof, and (B) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.